How are we assessing the safety and quality use of medicines used by young people in Australia?
Jane Bell, Andrew Wilson, Adam Elshaug, Natasha Nassar
JOURNAL OF PAEDIATRICS AND CHILD HEALTH | WILEY | Published : 2018
Awarded by National Health and Medical Research Council Career Development Fellowship
Awarded by Australia's National Health and Medical Research Council
We thank Professors Sallie Pearson and Nicholas Buckley for their helpful comments on earlier drafts of this commentary. Associate Professor Nassar is supported by a National Health and Medical Research Council Career Development Fellowship (no. 1067066). Professor Elshaug receives salary support as the HCF Research Foundation Professorial Research Fellow, and holds research grants from The Commonwealth Fund and Australia's National Health and Medical Research Council (ID 1109626 and 1104136). He receives consulting/sitting fees from Cancer Australia, the Capital Markets Cooperative Research Centre-Health Quality Program, NPS MedicineWise (facilitator of Choosing Wisely Australia), The Royal Australasian College of Physicians (facilitator of the EVOLVE program) and the Australian Commission on Safety and Quality in Health Care, and as a member of the Australian Government Department of Health's Medicare Benefits Schedule Review Taskforce. Professor Wilson is Chair of the Pharmaceutical Benefits Advisory Committee.